August 9, 2011
AlloSource Joins Alliance for Regenerative Medicine, Medical Device Manufacturers Association
CENTENNIAL, Colo., Aug. 9, 2011 /PRNewswire/ -- AlloSource, a leading developer, processor and distributor of bone and soft-tissue allografts for use in surgical procedures around the world, today announced two new key affiliations with the Alliance for Regenerative Medicine (ARM) and the Medical Device Manufacturers Association (MDMA). AlloSource pursued membership with both organizations in order to support medical device and regenerative medicine grassroots efforts with policy makers.
ARM is a nonprofit whose mission is to educate key policy makers about the potential of regenerative medicine and to advocate for favorable public policies to facilitate advances in the field. MDMA is a national trade association providing educational and advocacy assistance to innovative and entrepreneurial medical technology companies. Both organizations have already made progress in growing the knowledge base of Capitol Hill influencers on the current industry issues that affect their member organizations.
AlloSource recently expanded its product offerings with the addition of AlloStemÃ® Stem Cell Bone Growth Substitute, which pioneers the use of mesenchymal stem cells derived from donor adipose tissue for orthopedic applications, helping to stimulate natural bone formation. Through the osteobiologics products they produce, the company has facilitated approximately 100,000 live stem cell transplants worldwide, becoming the world's largest provider of stem cell tissue for surgeries.
"AlloSource is a leader in the regenerative medicine landscape thanks to its proprietary AlloStem product, which is creating exciting new opportunities for orthopedic patients," said Morrie Ruffin, Managing Director for the Alliance for Regenerative Medicine. "Our organization is eager to work together with AlloSource and others to educate key policymakers on the amazing potential of regenerative medicine."
"We are excited to work with AlloSource due to its proud track record in the bioscience industry and its nonprofit dedication to the healthcare community," said Mark Leahey, President and CEO of MDMA. "We look forward to AlloSource joining our efforts to share powerful stories from the medical device industry with members of Congress and the public, showcasing how innovation in our field supports patient care and job creation."
AlloSource is a non-profit company that offers more than 200 precise bone, skin, soft-tissue and custom-machined allografts for use in an array of life-saving and life-enhancing medical procedures. As the world's leader in fresh cartilage tissue used for joint repair and skin allografts to heal severe burns, AlloSource has grown into one of the largest tissue networks in the country with more than 350 employees. It is the world's largest processor of live cellular bone growth substitutes and delivers unparalleled expertise and customer service to its growing network of surgeons, partners and the country's most reputable organ procurement organizations. As one of the leading innovators in maximizing tissue donation with the goal of offering optimal solutions for healthcare providers and their patients, AlloSource is recognized by the medical community for its ability to process and provide high quality tissue. The company is accredited by the American Association of Tissue Banks (AATB) and is headquartered in Centennial, CO. For more information, please visit our corporate website or educational website.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.